Your browser doesn't support javascript.
COVID-19 infection in patients with connective tissue disease: A multicity study in Hubei province, China.
Ye, Cong; Zhong, Jixin; Cai, Shaozhe; Dong, Li; Li, Chuanjing; Hou, Xiaoqiang; Chen, Xiaoqi; Zhang, Anbing; Chen, Wenli; He, Dongchu; Zhou, Tao; Shang, Guilian; Chu, Aichun; Li, Huiling; Liu, Qihuan; Wu, Bin; Yu, Xiangdong; Peng, Tao; Wen, Cheng; Huang, Gang Hong; Huang, Hao; Huang, Qin; Su, Linchong; Chen, Wenping; Yang, Huiqin; Dong, Lingli.
  • Ye C; Department of Rheumatology and Immunology Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology Wuhan Hubei China.
  • Zhong J; Department of Rheumatology and Immunology Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology Wuhan Hubei China.
  • Cai S; Department of Rheumatology and Immunology Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology Wuhan Hubei China.
  • Dong L; Jingzhou City Central Hospital of Hubei Province Jingzhou Hubei China.
  • Li C; Department of Rheumatology Xiaogan Hospital Affiliated to Wuhan University of Science and Technology Xiaogan Hubei China.
  • Hou X; The First College of Clinical Medical Sciences China Three Gorges University Yichang Hubei China.
  • Chen X; Department of Rheumatology Zhongnan Hospital of Wuhan University Wuhan Hubei China.
  • Zhang A; Department of Rheumatology and Immunology Xiangyang Central Hospital Xiangyang Hubei China.
  • Chen W; Department of Rheumatology and Immunology Wuhan Central Hospital Wuhan Hubei China.
  • He D; Department of Integrated Treatment General Hospital of Central Theater Command Wuhan Hubei China.
  • Zhou T; Department of Rheumatology and Immunology Wuhan Puren Hospital Affiliated to Wuhan University of Science and Technology Wuhan Hubei China.
  • Shang G; Department of Rheumatology and Immunology Tianyou Hospital Affiliated to Wuhan University of Science and Technology Wuhan Hubei China.
  • Chu A; Department of Prevention and Health Care Renmin Hospital of Wuhan University Wuhan Hubei China.
  • Li H; Department of Rheumatology and Immunology The Traditional Chinese Medical Hospital of Hubei Province Wuhan Hubei China.
  • Liu Q; Department of Rheumatology and Immunology Affliated Dongfeng Hospital Hubei University of Medicine Shiyan Hubei China.
  • Wu B; Department of Rheumatology and Immunology The First People's Hospital of Jingzhou Jingzhou Hubei China.
  • Yu X; Department of Rheumatology and Immunology Huangshi Central Hospital of Edong Healthcare Group Huangshi Hubei China.
  • Peng T; Department of Rheumatology and Immunology Hankou Hospital of Wuhan Wuhan Hubei China.
  • Wen C; Department of Endocrinology Xiaogan First People's Hospital Xiaogan Hubei China.
  • Huang GH; Department of Rheumatology and Immunology China Resources and Wisco General Hospital Wuhan Hubei China.
  • Huang H; Department of Rheumatology and Immunology The First People's Hospital of Tianmen Tianmen Hubei China.
  • Huang Q; Department of Nephrology and Rheumatology Enshi Tujia and Miao Autonomous Prefecture Central Hospital Enshi Hubei China.
  • Su L; Department of Rheumatology and Immunology Minda Hospital of Hubei Minzu University Enshi Hubei China.
  • Chen W; Department of Rheumatology and Immunology Huanggang Central HospitaI Huanggang Hubei China.
  • Yang H; Department of Rheumatology and Immunology Wuhan No.1 Hospital Wuhan Hubei China.
  • Dong L; Department of Rheumatology and Immunology Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology Wuhan Hubei China.
MedComm (2020) ; 2(1): 82-90, 2021 Mar.
Article in English | MEDLINE | ID: covidwho-1062116
ABSTRACT
Novel Coronavirus disease 2019 (COVID-19) has spread rapidly around the world. Individuals with immune dysregulation and/or on immunosuppressive therapy, such as rheumatic patients, are considered at greater risk for infections. However, the risks of patients with each subcategory of rheumatic diseases have not been reported. Here, we identified 100 rheumatic patients from 18,786 COVID-19 patients hospitalized in 23 centers affiliated to Hubei COVID-19 Rheumatology Alliance between January 1 and April 1, 2020. Demographic information, medical history, length of hospital stay, classification of disease severity, symptoms and signs, laboratory tests, disease outcome, computed tomography, and treatments information were collected. Compared to gout and ankylosing spondylitis (AS) patients, patients with connective tissue disease (CTD) tend to be more severe after COVID-19 infection (p = 0.081). CTD patients also had lower lymphocyte counts, hemoglobin, and platelet counts (p values were 0.033, < 0.001, and 0.071, respectively). Hydroxychloroquine therapy and low- to medium-dose glucocorticoids before COVID-19 diagnosis reduced the progression of COVID-19 to severe/critical conditions (p = 0.001 for hydroxychloroquine; p = 0.006 for glucocorticoids). Our data suggests that COVID-19 in CTD patients may be more severe compared to patients with AS or gout.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: MedComm (2020) Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: MedComm (2020) Year: 2021 Document Type: Article